Insulin makers cut prices, but will profits still rise?

Novo Nordisk and Eli Lilly have promised to slash the price of life-saving insulin by up to 75% and 70%, respectively, while Sanofi, which produces widely-prescribed Lantus, is the final holdout among the three companies that produce 90% of the world's insulin market by value. Insulin prices charged by the three major drug manufacturers spiked over the past two decades, and the prices have increasingly been scrutinized by analysts, politicians, and patient advocates. A federal policy that would cap the cost of insulin is being pushed by T1International, an advocacy organization for people with Type 1 diabetes.